赛生药业获得再鼎医药“瑞普替尼”中国大陆独家推广权

丁香园 Insight 数据库01-08

1 月 8 日消息，赛生药业宣布已于近日与再鼎医药达成合作，获得新一代酪氨酸激酶抑制剂（TKI）瑞普替尼在中国大陆的独家推广权，双方将携手推进该创新药物在中国市场的商业化。截图来源：赛生药业官微瑞普替尼是一款靶向作用于 ROS1 和 NTRK 致癌因子的新一代 TKI。2020 年 7 月，再鼎医药与 Turning Point（已被 BMS 收购）达成一项1.76 亿美元的独家授权协议，获得...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2602639763?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-08 11:52","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2602639763","market":"hk","top_or_hot":-1,"title":"赛生药业获得再鼎医药“瑞普替尼”中国大陆独家推广权","media":"丁香园 Insight 数据库","content":"<div>\n<p>1 月 8 日消息，赛生药业宣布已于近日与再鼎医药达成合作，获得新一代酪氨酸激酶抑制剂（TKI）瑞普替尼在中国大陆的独家推广权，双方将携手推进该创新药物在中国市场的商业化。截图来源：赛生药业官微瑞普替尼是一款靶向作用于 ROS1 和 NTRK 致癌因子的新一代 TKI。2020 年 7 月，再鼎医药与 Turning Point（已被 BMS 收购）达成一项1.76 亿美元的独家授权协议，获得...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108140004a4aab112&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>赛生药业获得再鼎医药“瑞普替尼”中国大陆独家推广权</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n赛生药业获得再鼎医药“瑞普替尼”中国大陆独家推广权\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-08 11:52 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108140004a4aab112&s=b><strong>丁香园 Insight 数据库</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>1 月 8 日消息，赛生药业宣布已于近日与再鼎医药达成合作，获得新一代酪氨酸激酶抑制剂（TKI）瑞普替尼在中国大陆的独家推广权，双方将携手推进该创新药物在中国市场的商业化。截图来源：赛生药业官微瑞普替尼是一款靶向作用于 ROS1 和 NTRK 致癌因子的新一代 TKI。2020 年 7 月，再鼎医药与 Turning Point（已被 BMS 收购）达成一项1.76 亿美元的独家授权协议，获得...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108140004a4aab112&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108140004a4aab112&s=b","article_id":"2602639763","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108140004a4aab112&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602639763","pubTimestamp":1767844349,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"1 月 8 日消息，赛生药业宣布已于近日与再鼎医药达成合作，获得新一代酪氨酸激酶抑制剂 瑞普替尼在中国大陆的独家推广权，双方将携手推进该创新药物在中国市场的商业化。2020 年 7 月，再鼎医药与 Turning Point达成一项1.76 亿美元的独家授权协议，获得瑞普替尼在大中华区的独家开发及商业化权。2024 年 5 月，瑞普替尼获中国 NMPA 批准上市，用于治疗ROS1 阳性的局部晚期或转移性非小细胞肺癌成人患者。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","09688":"再鼎医药","BK1191":"制药","BK1588":"回港中概股","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"Saisheng Pharmaceutical obtains the exclusive promotion rights of Zai Lab's \"Riprotinib\" in mainland China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":1.5},"content_text":"1 月 8 日消息，赛生药业宣布已于近日与再鼎医药达成合作，获得新一代酪氨酸激酶抑制剂（TKI）瑞普替尼在中国大陆的独家推广权，双方将携手推进该创新药物在中国市场的商业化。截图来源：赛生药业官微瑞普替尼是一款靶向作用于 ROS1 和 NTRK 致癌因子的新一代 TKI。2020 年 7 月，再鼎医药与 Turning Point（已被 BMS 收购）达成一项1.76 亿美元的独家授权协议，获得瑞普替尼在大中华区的独家开发及商业化权。2024 年 5 月，瑞普替尼获中国 NMPA 批准上市，用于治疗ROS1 阳性的局部晚期或转移性非小细胞肺癌成人患者。该适应症于 2025 年 1 月被纳入国家医保药品目录。2026 年 1 月，瑞普替尼又获 NMPA 批准用于治疗NTRK 基因融合的成人实体瘤患者。TRIDENT-1 研究显示，瑞普替尼针对 TKI 初治、TKI 经治和颅内转移的 ROS1 阳性非小细胞肺癌患者都具有高缓解率和良好的持久性。此外，该研究还显示出瑞普替尼在 NTRK 基因融合实体瘤患者中具有显著且持久的有效性以及可控的安全性特征。封面来源：企业 Logo","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602639763","isCrawlerRequest":true}